BRPI0715504A2 - Métodos e preparações farmacêuticas a fim de contribuir para o tratamento de neuropatia induzida por quimioterapia. - Google Patents

Métodos e preparações farmacêuticas a fim de contribuir para o tratamento de neuropatia induzida por quimioterapia. Download PDF

Info

Publication number
BRPI0715504A2
BRPI0715504A2 BRPI0715504-2A BRPI0715504A BRPI0715504A2 BR PI0715504 A2 BRPI0715504 A2 BR PI0715504A2 BR PI0715504 A BRPI0715504 A BR PI0715504A BR PI0715504 A2 BRPI0715504 A2 BR PI0715504A2
Authority
BR
Brazil
Prior art keywords
cisplatin
leteprinim
pharmaceutical preparation
administration
treatment
Prior art date
Application number
BRPI0715504-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Guru Reddy
Dorla Mirejovsky
Luigi Lenaz
Original Assignee
Spectrum Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spectrum Pharmaceuticals Inc filed Critical Spectrum Pharmaceuticals Inc
Publication of BRPI0715504A2 publication Critical patent/BRPI0715504A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0715504-2A 2006-08-01 2007-08-01 Métodos e preparações farmacêuticas a fim de contribuir para o tratamento de neuropatia induzida por quimioterapia. BRPI0715504A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82108206P 2006-08-01 2006-08-01
US60/821.082 2006-08-01
PCT/US2007/075008 WO2008017000A2 (en) 2006-08-01 2007-08-01 Methods and pharmaceutical preparations for contributing to the treatment of chemotherapy-induced neuropathy

Publications (1)

Publication Number Publication Date
BRPI0715504A2 true BRPI0715504A2 (pt) 2014-05-06

Family

ID=38744846

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0715504-2A BRPI0715504A2 (pt) 2006-08-01 2007-08-01 Métodos e preparações farmacêuticas a fim de contribuir para o tratamento de neuropatia induzida por quimioterapia.

Country Status (12)

Country Link
EP (1) EP2046335A2 (enExample)
JP (1) JP2009545619A (enExample)
KR (1) KR20090047501A (enExample)
CN (1) CN101657199A (enExample)
BR (1) BRPI0715504A2 (enExample)
CA (1) CA2659477A1 (enExample)
IL (1) IL196824A0 (enExample)
MX (1) MX2009001116A (enExample)
NO (1) NO20090279L (enExample)
RU (1) RU2009107123A (enExample)
WO (1) WO2008017000A2 (enExample)
ZA (1) ZA200900728B (enExample)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002004448A2 (en) * 2000-07-07 2002-01-17 Neotherapeutics, Inc. Methods for treatment of drug-induced peripheral neuropathy and related conditions

Also Published As

Publication number Publication date
EP2046335A2 (en) 2009-04-15
IL196824A0 (en) 2009-11-18
RU2009107123A (ru) 2010-09-10
MX2009001116A (es) 2009-02-10
CA2659477A1 (en) 2008-02-07
KR20090047501A (ko) 2009-05-12
WO2008017000A3 (en) 2008-03-20
WO2008017000A8 (en) 2009-04-30
ZA200900728B (en) 2010-03-31
CN101657199A (zh) 2010-02-24
NO20090279L (no) 2009-02-26
JP2009545619A (ja) 2009-12-24
WO2008017000A2 (en) 2008-02-07

Similar Documents

Publication Publication Date Title
Takeshita et al. Prevention of salt-induced hypertension in the Dahl strain by 6-hydroxydopamine
JP6047092B2 (ja) 新規癌治療法としてのアリール炭化水素受容体（ＡｈＲ）改変物質
US5874420A (en) Process for regulating vagal tone
AU666773B2 (en) Anti-arrhythmic, analgesically acting phthalazinone derivatives that break through multi-drug resistance
KR20180116298A (ko) 화학요법 유도 심장독성에 대응하기 위한 약제학적 조성물 및 방법
PT2421536E (pt) Métodos de tratamento para tumores sólidos
US12201608B2 (en) Methods for treating Parkinson's disease by administering resiniferatoxin
ES2914060T3 (es) Combinación de dofetilida y mexiletina para la prevención y el tratamiento de la fibrilación auricular
KR20240013092A (ko) 화학요법-유도된 말초 신경병증과 관련된 통증 치료
JP2006519823A (ja) 疼痛治療のための化合物
US20080207557A1 (en) Methods of Decreasing or Preventing Pain Using Spicamycin Derivatives
US11352382B2 (en) Mito-lonidamine, compositions and methods of use
ES2374503T3 (es) Acetil l-carnitina para la prevención y/o el tratamiento de las neuropatías periféricas inducidas por talidomida.
JP2009534360A (ja) アルファ−ケトグルタレートを含む組成物およびその筋性能を調節するための使用
Wu et al. Enhancing KCNQ channel activity improves neurobehavioral recovery after spinal cord injury
Arguello et al. Preclinical evaluation of 9-chloro-2-methylellipticinium acetate alone and in combination with conventional anticancer drugs for the treatment of human brain tumor xenografts
WO2008017000A2 (en) Methods and pharmaceutical preparations for contributing to the treatment of chemotherapy-induced neuropathy
Iraz et al. Role of vagal activity on bradicardic and hypotensive effects of caffeic acid phenethyl ester (CAPE)
EP2568807B1 (en) Phenoxyalkyl pyridinium oxime therapeutics for treatment of organophosphate poisoning
JP2022523053A (ja) ミトコンドリアを標的とするイソケタール／イソレブグランジンスカベンジャー
RU2523792C1 (ru) Лекарственное средство для лечения туберкулеза
Popović et al. Effects of metformin and its combinations with other repurposed drugs on fibrosarcoma in hamsters
RU2436572C2 (ru) Комбинация ингибиторов гистондеацетилазы и излучения
JP6243850B2 (ja) 抗がん剤による末梢神経障害の予防、治療、または軽減剤
Roberts et al. Response of L1210 Leukemia to Treatment with 1, 3-Bis (2-chloroethyl)-1-nitrosourea plus 4′-Demethylepipodophyllotoxin-9-(4, 6-O-2-thenylidene-β-d-glucopyranoside)

Legal Events

Date Code Title Description
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 6A E 7A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2277 DE 26/08/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A, 8A, 9A, 10A, 11A, 12A E 13A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.